Arbutus Biopharma vs Enanta Pharmaceuticals
ABUS and ENTA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABUS and ENTA compare
Arbutus Biopharma is the larger company, worth 2.3 times as much as Enanta Pharmaceuticals ($768M against $338M).
Arbutus Biopharma keeps more of each dollar of sales as profit, with a net margin of 121% compared with −96.9% at Enanta Pharmaceuticals.
Arbutus Biopharma scores higher on the StockData Score (12 against 2 for Enanta Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABUS | ENTA |
|---|---|---|
| Size and price | ||
| Market cap | $768M | $338M |
| Share price | $3.88 | $11.60 |
| Change, 1 year | −15.5% | 0.78% |
| Change, 5 years | 17.6% | −84.6% |
| Beta (5Y) | 0.55 | 1.15 |
| Employees | 19 | 120 |
| StockData Score | ||
| Total score | 12 (better) | 2 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 3 (better) | 1 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 3.5× | – |
| P/S | 4.2× (better) | 5.2× |
| P/B | 9.0× | 3.3× (better) |
| EV/EBITDA | 2.9× | – |
| FCF yield | – | −10.9% |
| Fair value | $21.71 | $9.56 |
| Margin of safety | 82.1% (better) | −21.3% |
| Growth | ||
| Revenue growth (TTM) | 1143% | – |
| Revenue growth, 5Y average | 15.3% (better) | −11.8% |
| Profitability | ||
| Operating margin | 81.1% (better) | −90.0% |
| Net margin | 121% (better) | −96.9% |
| FCF margin | – | −56.6% |
| Return on equity | 270% (better) | −70.1% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | 2299× (better) | −4.5× |
| Current ratio | 1.40 | 3.76 (better) |
| Altman Z-score | −0.64 (better) | −0.91 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 71.1% | 93.6% |
| Held by insiders | 35.9% | 7.9% |
| Insider net buying, 12 months | – | −$183K |
| Short interest, % of float | 15.7% | 6.9% |
Go deeper
- ABUS stock overview
- ABUS income statement
- ABUS valuation and score
- ENTA stock overview
- ENTA income statement
- ENTA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.